Toward the development of a protein-based group B Streptococcus vaccine

Clinical trials of protein-based vaccines to prevent Group B streptococcal infections are underway. In this issue of Cell Reports Medicine, Pawlowski et al.(1) provide an extensive characterization of the immune response generated by the recently tested GBS-NN vaccine.